Atrium Therapeutics (RNA) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($143.7 million vs $125.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RNA | TNXP |
|---|---|---|
| Share price | $8.40 | $7.30 |
| Market cap | $143.69M | $125.20M |
| 1-day change | +1.69% | +0.27% |
| YTD return | — | -53.39% |
| 1-year return | — | -67.63% |
| 5-year return | — | -100.00% |
| EPS (TTM) | $-5.44 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.77 | $22.38 |
| 52-week low | $7.63 | $7.10 |
| Distance from 52-week high | -49.91% | -67.38% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +197.62% | +509.59% |
| Average volume | 259.35K | 542.97K |
| Shares outstanding | 17.11M | 17.15M |
| Employees | — | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
RNA vs TNXP FAQ
Which is bigger, Atrium Therapeutics or Tonix Pharmaceuticals?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $143.69M compared with $125.20M for Tonix Pharmaceuticals (TNXP).
Are Atrium Therapeutics and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.